Ikena Oncology Inc

-0.60 (-5.38%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)82.50M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.05 Million
Adjusted EPS-$0.42
See more estimates
10-Day MA$11.57
50-Day MA$12.37
200-Day MAN/A
See more pivots

Ikena Oncology Inc Stock, NASDAQ:IKNA

645 Summer Street, Suite 101, Boston, Massachusetts 02210
United States of America
Phone: +1.857.273.8343
Number of Employees: 33


Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.